Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 31:10:621.
doi: 10.3389/fphar.2019.00621. eCollection 2019.

Antitumor Cannabinoid Chemotypes: Structural Insights

Paula Morales  1 , Nadine Jagerovic  1
Affiliations

Antitumor Cannabinoid Chemotypes: Structural Insights

Paula Morales et al. Front Pharmacol. .

Abstract

Cannabis has long been known to limit or prevent nausea and vomiting, lack of appetite, and pain. For this reason, cannabinoids have been successfully used in the treatment of some of the unwanted side effects caused by cancer chemotherapy. Besides their palliative effects, research from the past two decades has demonstrated their promising potential as antitumor agents in a wide variety of tumors. Cannabinoids of endogenous, phytogenic, and synthetic nature have been shown to impact the proliferation of cancer through the modulation of different proteins involved in the endocannabinoid system such as the G protein-coupled receptors CB1, CB2, and GRP55, the ionotropic receptor TRPV1, or the fatty acid amide hydrolase (FAAH). In this article, we aim to structurally classify the antitumor cannabinoid chemotypes described so far according to their targets and types of cancer. In a drug discovery approach, their in silico pharmacokinetic profile has been evaluated in order to identify appropriate drug-like profiles, which should be taken into account for further progress toward the clinic. This analysis may provide structural insights into the selection of specific cannabinoid scaffolds for the development of antitumor drugs for the treatment of particular types of cancer.

Keywords: ADMET; cancer; cannabinoid; chemotype; in silico.

PubMed Disclaimer

References

    1. A phase 1 study of dexanabinol in patients with advanced solid tumours, ClinicalTrials.gov; Available at: https://clinicaltrials.gov/ct2/show/NCT01489826?term=Dexanabinol&rank=3 (Accessed February 27, 2019).
    1. A pilot study of dronabinol for adult patients with primary gliomas, ClinicalTrials.gov, Available at: https://clinicaltrials.gov/ct2/show/results/NCT00314808?​term=cannabinoi... (Accessed February 28, 2019).
    1. Andradas C., Caffarel M. M., Pérez-Gómez E., Salazar M., Lorente M., Velasco G., et al. (2011). The orphan G protein–coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30, 245–252. 10.1038/onc.2010.402 - DOI - PubMed
    1. Badolato M., Carullo G., Caroleo M. C., Cione E., Aiello F., Manetti F. (2019). Discovery of 1,4-naphthoquinones as a new class of antiproliferative agents targeting GPR55. ACS Med. Chem. Lett., 10 (4), 402–406. 10.1021/acsmedchemlett.8b00333 - DOI - PMC - PubMed
    1. Badowski M. E. (2017). A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother. Pharmacol. 80 (3), 441–449. 10.1007/s00280-017-3387-5 - DOI - PMC - PubMed